Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics Inc is experiencing significant operational growth, as evidenced by a 52% year-over-year increase in operating expenses to $7 million in Q2 FY25, which indicates the company is investing heavily in its expansion strategies. The company’s innovative business model demonstrates the potential for 4-6 times more revenue per case while also improving access to a larger patient base and maintaining healthy profit margins. Additionally, positive pilot results with Rebis Health highlight the company's ability to establish partnerships with sleep testing centers, further enhancing its market presence and revenue-generating capabilities.

Vivos Therapeutics LLC reported Q2 FY25 revenues of $3.8 million, falling short of expectations and reflecting a year-over-year decline of 6%, despite a quarter-over-quarter increase of 27%. Moreover, the company has revised its FY25 EPS estimates downward to $(2.13) from $(1.54), driven by increased operating expenses, with pro forma EPS reported at $(0.55), significantly worse than both internal and consensus forecasts. The financial outlook is further complicated by risks associated with low visibility and the potential for further dilution due to financing activities.